IMMUNEONCO-B (01541) saw its shares surge more than 16%. At the time of writing, the stock was up 15.87% to HK$4.38, with a turnover of HK$9.47 million. The catalyst for the movement was news on March 4th, when the company announced that the Investigational New Drug (IND) application for its self-developed Amurefup α subcutaneous injection (IMM0306S), intended for the treatment of Systemic Lupus Erythematosus (SLE), has received formal approval from China's National Medical Products Administration (NMPA). This milestone development signifies a major breakthrough for IMMUNEONCO in the research and development of innovative drugs for autoimmune diseases. The IND approval for IMM0306S to treat SLE represents the latest achievement in the company's intensive focus on the autoimmune disease area and is a key manifestation of its strategy for a comprehensive and flourishing autoimmune pipeline. In recent years, leveraging its "mAb-Trap" technology platform, IMM0306 has made critical progress across several major autoimmune indications, building a rich and deep product pipeline.